Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RR001 in Combination With Chemotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study

NCT06861452 is registered in ClinicalTrials.gov with EIR Biotherapies s.r.l. as lead sponsor.

NCT NCT06861452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06861452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RR001 in Combination With Chemotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Open-label, Non-randomized Dose Escalation Phase I/IIa Study
Lead sponsor
EIR Biotherapies s.r.l.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 25, 2025
Completion date
January 29, 2028
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma